Pharmaceutical manufacturing capacity
Grand River Aseptic Manufacturing (GRAM) is constructing its third pharmaceutical manufacturing facility in Grand Rapids, Michigan, US.
Announced in October 2018, the new facility is being developed with an estimated investment of more than $60m. GRAM other two facilities in Grand Rapids are running at near capacity.
The new facility will substantially expand GRAM’s existing 40,000ft2 manufacturing and finishing space. It will improve the company’s automation capabilities and enable it to meet the growing demand for its products in the aseptic manufacturing market.
The project is expected to create 107 new jobs and support the pharmaceutical manufacturing sector in West Michigan.
The new pharmaceutical manufacturing facility will be located at 524 Butterworth St. SW in Grand Rapids.
GRAM purchased a 1.5-acre parcel in the town near its existing facilities on Godfrey Street and Front Avenue.
GRAM signed purchase agreements with two separate parties to acquire the land in March 2018. The company explored a number of locations in other states before deciding to expand in Grand Rapids due to the availability of a strong workforce and business environment.
The new facility will have a built-up area of 62,400ft2 and will have enough production space for high-speed, fully-integrated pharmaceutical manufacturing and packaging lines. The facility will also include state-of-the-art cleanroom space, featuring new isolator technology.
The Michigan Economic Development Corporation (MEDC) and West Michigan’s economic development organisation The Right Place worked in collaboration to assist GRAM’s operations expansion in Grand Rapids.
The MEDC approved a $1m performance-based grant under the Michigan Business Development Program for the new pharmaceutical manufacturing facility. A local P.A. 198 tax abatement from the City of Grand Rapids will also support the project development.
Arlington Capital Partners, a private equity firm based in Washington, which is a majority owner of GRAM, will also provide funding to expand the facility.
GRAM’s manufacturing facility in Front Avenue is an 11,400ft2 US Food and Drug Administration (FDA) approved current good manufacturing practice (cGMP) compliant facility.
GRAM expanded the capacity of the plant with the addition of a new Colanar FSV syringe filler in March 2018 and a Bausch+Ströbel filler with SKAN isolator in April 2018.
The high-speed Bausch+Ströbel filler can fill 200 vials a minute ranging from 2ml to 50ml. It is equipped with a vial washer, a depyrogenation tunnel and a filling machine.
The 28,000ft2 finishing facility in Godfrey Street was opened in August 2014. It includes inspection, labelling, packaging and storage areas, as well as a large laboratory.
GRAM provides parenteral services such as pharmaceutical development and manufacturing, analytical testing and regulatory filing support.
The company extends its formulation development and process development capabilities to develop large and small molecule products. It provides cGMP capabilities and assists in the commercialisation of the product.
The company’s external testing laboratories enhance the analytical testing of products, including raw materials, finished products and stability samples.
Lonza has developed a new biomanufacturing complex at its biopark in Visp, Switzerland. Located in Valais, the biomanufacturing complex features…
Janssen Sciences Ireland has expanded its biomedicines manufacturing facility in Barnahely, Ringaskiddy in County Cork, Ireland, with the addition of…
US-based healthcare company Grail is building a state-of-the-art laboratory facility in the Research Triangle Park (RTP), North Carolina. The facility will…
In July 2019, the UK-based Wasdell Group (Wasdell) opened a state-of-the-art pharmaceutical packaging plant in Dundalk, Ireland. Built with an…